Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vecabrutinib - Viracta Therapeutics

Next Previous
Drug Profile

Vecabrutinib - Viracta Therapeutics

Alternative Names: SNS 062; SNS-062-succinate; Vecabrutinib succinate - Viracta Therapeutics

Latest Information Update: 16 Oct 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biogen Idec; Sunesis Pharmaceuticals
  • Developer Biogen; Viracta Therapeutics
  • Class Amides; Amines; Aniline compounds; Antineoplastics; Chlorinated hydrocarbons; Fluorinated hydrocarbons; Piperidines; Pyrimidines; Small molecules; Succinates
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Emt protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cancer; Graft-versus-host disease; Haematological malignancies

Most Recent Events

  • 05 Feb 2025 Discontinued - Preclinical for Cancer in USA (PO)
  • 05 Feb 2025 Discontinued - Preclinical for Graft-versus-host disease in USA (PO)
  • 07 Apr 2023 Preclinical trials in Cancer in USA (PO) (Viracta Therapeutics pipeline, April 2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top